Oral Session 1-5B AML: Novel agents

[OS1-5B-2] Improved survival with glasdegib in myeloid cancer patients who did not achieve complete remission

Jorge E Cortes¹, Florian H Heidel^2,3, Walter Fiedler⁴, B. Douglas Smith⁵, Tadeusz Robak⁶, Pau Montesinos^7,8, Anna Candoni⁹, Brian Leber¹⁰, Mikkael A Sekeres¹¹, Daniel A. Pollyea¹², Mirjana Zeremski¹³, Weidong Wendy Ma¹³, Thomas O'Brien¹³, Ashleigh O'Connell¹³, Geoffrey Chan¹³, Michael Heuser¹⁴ (1.Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, United States of America, 2.Otto-von-Guericke University Medical Center Magdeburg, Magdeburg, Federal Republic of Germany, 3.Internal Medicine II, University Hospital Jena, Jena, Federal Republic of Germany, 4.Department of Hematology and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Federal Republic of Germany, 5.Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, United States of America, 6.Department of Hematology, Medical University of Lodz, Lodz, Republic of Poland, 7.Hospital Universitari i Politecnic La Fe, Valencia, Spain, 8.CIBERONC, Instituto Carlos III, Madrid, Spain, 9.Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italian Republic, 10.Juravinski Hospital at Hamilton Health Sciences, Hamilton, Canada, 11.Leukemia Program, Cleveland Clinic, Cleveland, United States of America, 12.Division of Hematology, University of Colorado School of Medicine, Aurora, United States of America, 13.Pfizer Oncology, New York, United States of America, 14.Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Federal Republic of Germany)